Mitchell S. Kapoor
Stock Analyst at HC Wainwright & Co.
(3.92)
# 701
Out of 5,157 analysts
82
Total ratings
46.58%
Success rate
12.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mitchell S. Kapoor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INCY Incyte | Reiterates: Buy | $135 | $92.22 | +46.39% | 3 | Mar 9, 2026 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $25 → $30 | $12.66 | +136.97% | 7 | Mar 3, 2026 | |
| CBIO Crescent Biopharma | Maintains: Buy | $25 → $22 | $12.09 | +81.97% | 3 | Mar 2, 2026 | |
| SRPT Sarepta Therapeutics | Reiterates: Sell | $5 | $16.94 | -70.48% | 4 | Mar 2, 2026 | |
| BMRN BioMarin Pharmaceutical | Reiterates: Neutral | $55 | $59.97 | -8.29% | 5 | Mar 2, 2026 | |
| SMMT Summit Therapeutics | Maintains: Buy | $40 → $30 | $15.58 | +92.55% | 8 | Feb 24, 2026 | |
| TYRA Tyra Biosciences | Maintains: Buy | $30 → $45 | $34.84 | +29.16% | 2 | Feb 17, 2026 | |
| EVMN Evommune | Maintains: Buy | $35 → $65 | $23.29 | +179.09% | 2 | Feb 10, 2026 | |
| KRRO Korro Bio | Upgrades: Buy | $20 | $11.55 | +73.16% | 3 | Jan 29, 2026 | |
| LEGN Legend Biotech | Maintains: Buy | $60 → $50 | $19.45 | +157.07% | 2 | Jan 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $25 | $16.89 | +48.02% | 2 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $70 | $22.12 | +216.46% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $6.52 | +53.37% | 4 | Jan 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $20 → $40 | $25.16 | +58.98% | 3 | Jan 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.72 | - | 4 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $90 | $64.40 | +39.75% | 5 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $20 → $45 | $24.55 | +83.30% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $7.59 | +163.50% | 1 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $40 → $30 | $8.13 | +269.23% | 1 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $10 | $4.73 | +111.42% | 1 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $110 | $72.69 | +51.33% | 6 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $20 | $8.93 | +123.96% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $45 → $40 | $32.98 | +21.29% | 2 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $80 | $48.64 | +64.47% | 1 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $2.52 | +98.41% | 2 | Sep 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $7 | $1.59 | +340.25% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3 → $2 | $6.72 | -70.24% | 1 | Aug 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.14 | +250.88% | 1 | Aug 11, 2025 |
Incyte
Mar 9, 2026
Reiterates: Buy
Price Target: $135
Current: $92.22
Upside: +46.39%
Intellia Therapeutics
Mar 3, 2026
Maintains: Buy
Price Target: $25 → $30
Current: $12.66
Upside: +136.97%
Crescent Biopharma
Mar 2, 2026
Maintains: Buy
Price Target: $25 → $22
Current: $12.09
Upside: +81.97%
Sarepta Therapeutics
Mar 2, 2026
Reiterates: Sell
Price Target: $5
Current: $16.94
Upside: -70.48%
BioMarin Pharmaceutical
Mar 2, 2026
Reiterates: Neutral
Price Target: $55
Current: $59.97
Upside: -8.29%
Summit Therapeutics
Feb 24, 2026
Maintains: Buy
Price Target: $40 → $30
Current: $15.58
Upside: +92.55%
Tyra Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $30 → $45
Current: $34.84
Upside: +29.16%
Evommune
Feb 10, 2026
Maintains: Buy
Price Target: $35 → $65
Current: $23.29
Upside: +179.09%
Korro Bio
Jan 29, 2026
Upgrades: Buy
Price Target: $20
Current: $11.55
Upside: +73.16%
Legend Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $60 → $50
Current: $19.45
Upside: +157.07%
Jan 15, 2026
Reiterates: Buy
Price Target: $25
Current: $16.89
Upside: +48.02%
Jan 13, 2026
Reiterates: Buy
Price Target: $70
Current: $22.12
Upside: +216.46%
Jan 13, 2026
Maintains: Buy
Price Target: $13 → $10
Current: $6.52
Upside: +53.37%
Jan 9, 2026
Reiterates: Buy
Price Target: $20 → $40
Current: $25.16
Upside: +58.98%
Jan 7, 2026
Downgrades: Neutral
Price Target: n/a
Current: $8.72
Upside: -
Dec 19, 2025
Reiterates: Buy
Price Target: $90
Current: $64.40
Upside: +39.75%
Dec 9, 2025
Upgrades: Buy
Price Target: $20 → $45
Current: $24.55
Upside: +83.30%
Nov 24, 2025
Initiates: Buy
Price Target: $20
Current: $7.59
Upside: +163.50%
Nov 19, 2025
Maintains: Buy
Price Target: $40 → $30
Current: $8.13
Upside: +269.23%
Nov 11, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $4.73
Upside: +111.42%
Nov 10, 2025
Maintains: Buy
Price Target: $100 → $110
Current: $72.69
Upside: +51.33%
Oct 27, 2025
Maintains: Buy
Price Target: $10 → $20
Current: $8.93
Upside: +123.96%
Oct 27, 2025
Maintains: Buy
Price Target: $45 → $40
Current: $32.98
Upside: +21.29%
Sep 23, 2025
Reiterates: Buy
Price Target: $80
Current: $48.64
Upside: +64.47%
Sep 5, 2025
Reiterates: Buy
Price Target: $5
Current: $2.52
Upside: +98.41%
Aug 19, 2025
Reiterates: Buy
Price Target: $7
Current: $1.59
Upside: +340.25%
Aug 19, 2025
Maintains: Neutral
Price Target: $3 → $2
Current: $6.72
Upside: -70.24%
Aug 11, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.14
Upside: +250.88%